{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:26:21Z","timestamp":1791919581787,"version":"4.3.4"},"reference-count":208,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Colloids and Surfaces B: Biointerfaces"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.colsurfb.2025.115053","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T21:42:27Z","timestamp":1755553347000},"page":"115053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P2","title":["Unlocking the potential of lipid nanoparticles for enhanced glioma therapy: Recent advancements and future perspectives"],"prefix":"10.1016","volume":"256","author":[{"given":"Shiuli","family":"Bera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayeri Chatterjee","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1416-720X","authenticated-orcid":false,"given":"Moumita","family":"Kundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.colsurfb.2025.115053_bib1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011\u20132015","volume":"20","author":"Ostrom","year":"2018","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib2","first-page":"2050","article-title":"Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-\u03baB-dependent pathway","volume":"27","author":"Zhang","year":"2012","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.colsurfb.2025.115053_bib3","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013\u20132017","volume":"22","author":"Ostrom","year":"2020","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib4","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014\u20132018","volume":"23","author":"Ostrom","year":"2021","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib5","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib6","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.colsurfb.2025.115053_bib8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12916-016-0571-0","article-title":"Advances in immunotherapy for melanoma","volume":"14","author":"Redman","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.colsurfb.2025.115053_bib9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-Line immunotherapy for Non\u2013Small-Cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib10","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1158\/1078-0432.CCR-20-2833","article-title":"Cervical cancer immunotherapy: facts and hopes","volume":"27","author":"Ferrall","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.colsurfb.2025.115053_bib11","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 world health organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/jnen\/64.6.479","article-title":"Population-Based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas","volume":"64","author":"Ohgaki","year":"2005","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-011-0793-0","article-title":"Recent advances in the molecular understanding of glioblastoma","volume":"108","author":"Bleeker","year":"2012","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib14","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.bbcan.2014.05.004","article-title":"The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation","volume":"1846","author":"Molenaar","year":"2014","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.colsurfb.2025.115053_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1756-9966-32-59","article-title":"Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type","volume":"32","author":"Wang","year":"2013","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.colsurfb.2025.115053_bib16","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib17","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","article-title":"FDA drug approval summary: bevacizumab (Avastin\u00ae) as treatment of recurrent glioblastoma multiforme","volume":"14","author":"Cohen","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.colsurfb.2025.115053_bib18","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1158\/0008-5472.CAN-04-0083","article-title":"Disruption of cancer cell replication by alternating electric fields","volume":"64","author":"Kirson","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.colsurfb.2025.115053_bib19","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with Tumor-Treating fields plus temozolomide vs temozolomide alone for glioblastoma","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.colsurfb.2025.115053_bib20","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1586\/14737140.6.11.1593","article-title":"Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates","volume":"6","author":"Simpson","year":"2006","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.colsurfb.2025.115053_bib21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.wneu.2018.04.022","article-title":"Challenges in the treatment of glioblastoma: multisystem mechanisms of therapeutic resistance","volume":"116","author":"Noch","year":"2018","journal-title":"World Neurosurg."},{"key":"10.1016\/j.colsurfb.2025.115053_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrn1824","article-title":"Astrocyte\u2013endothelial interactions at the blood\u2013brain barrier","volume":"7","author":"Abbott","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.colsurfb.2025.115053_bib23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11481-006-9025-3","article-title":"Blood\u2013brain barrier: structural components and function under physiologic and pathologic conditions","volume":"1","author":"Persidsky","year":"2006","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib24","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2011.11.010","article-title":"Modern methods for delivery of drugs across the blood\u2013brain barrier","volume":"64","author":"Chen","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2025.115053_bib25","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the Blood\u2013Brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.colsurfb.2025.115053_bib26","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1124\/pr.117.014647","article-title":"Neuroimmune axes of the Blood\u2013Brain barriers and Blood\u2013Brain interfaces: bases for physiological regulation, disease states, and pharmacological interventions","volume":"70","author":"Erickson","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.colsurfb.2025.115053_bib27","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1208\/s12248-008-9055-2","article-title":"CNS delivery via adsorptive transcytosis","volume":"10","author":"Herv\u00e9","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.colsurfb.2025.115053_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/biom9010022","article-title":"Combination of Cell-Penetrating peptides with nanoparticles for therapeutic application: a review","volume":"9","author":"Silva","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.colsurfb.2025.115053_bib29","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1074\/jbc.272.25.16010","article-title":"A truncated HIV-1 tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus","volume":"272","author":"Viv\u00e8s","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.colsurfb.2025.115053_bib30","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1124\/pr.117.014647","article-title":"Neuroimmune axes of the Blood-Brain barriers and Blood-Brain interfaces: bases for physiological regulation, disease states, and pharmacological interventions","volume":"70","author":"Erickson","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.colsurfb.2025.115053_bib31","doi-asserted-by":"crossref","DOI":"10.2741\/s328","article-title":"Heterogeneity of cancer-initiating cells within glioblastoma","volume":"S4","author":"Vescovi","year":"2012","journal-title":"Front. Biosci."},{"key":"10.1016\/j.colsurfb.2025.115053_bib32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.colsurfb.2025.115053_bib33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.1239947","article-title":"Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma","volume":"343","author":"Johnson","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.colsurfb.2025.115053_bib34","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41583-018-0014-3","article-title":"A glial blueprint for gliomagenesis","volume":"19","author":"Laug","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.colsurfb.2025.115053_bib35","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.colsurfb.2025.115053_bib36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fonc.2019.00041","article-title":"Temozolomide induced hypermutation in glioma: evolutionary mechanisms and therapeutic opportunities","volume":"9","author":"Daniel","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib37","doi-asserted-by":"crossref","first-page":"5999","DOI":"10.1002\/cam4.1863","article-title":"Multiregional radiomics profiling from multiparametric MRI: identifying an imaging predictor of IDH1 mutation status in glioblastoma","volume":"7","author":"Li","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.colsurfb.2025.115053_bib38","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1093\/neuonc\/now113","article-title":"EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through src activation","volume":"18","author":"Eskilsson","year":"2016","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib39","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.1114033109","article-title":"Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response","volume":"109","author":"Szerlip","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.colsurfb.2025.115053_bib40","doi-asserted-by":"crossref","first-page":"16663","DOI":"10.18632\/oncotarget.4389","article-title":"TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma","volume":"6","author":"Mosrati","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.colsurfb.2025.115053_bib41","first-page":"5821","article-title":"Identification of a cancer stem cell in human brain tumors","volume":"63","author":"Singh","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.colsurfb.2025.115053_bib42","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1158\/0008-5472.CAN-10-4269","article-title":"Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells","volume":"71","author":"Zhu","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.colsurfb.2025.115053_bib43","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.bbagen.2012.10.008","article-title":"The cancer stem cell niche(s): the crosstalk between glioma stem cells and their microenvironment","volume":"1830","author":"Filatova","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.colsurfb.2025.115053_bib44","doi-asserted-by":"crossref","first-page":"415","DOI":"10.14740\/jocmr3781","article-title":"Glioblastoma stem cells and comparison of isolation methods","volume":"11","author":"Dundar","year":"2019","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.colsurfb.2025.115053_bib45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/stem.261","article-title":"Notch promotes radioresistance of glioma stem cells","volume":"28","author":"Wang","year":"2010","journal-title":"Stem Cells"},{"key":"10.1016\/j.colsurfb.2025.115053_bib46","first-page":"HY27","article-title":"Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 May decrease their chemoresistance","volume":"16","author":"Li","year":"2010","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.colsurfb.2025.115053_bib47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41568-019-0226-5","article-title":"Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets","volume":"20","author":"Bi","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.colsurfb.2025.115053_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122026","article-title":"Tumor microenvironment targeting system for glioma treatment via fusion cell membrane coating nanotechnology","volume":"295","author":"Ma","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.colsurfb.2025.115053_bib49","article-title":"Cancer cell membrane camouflaged nanoprobe for catalytic ratiometric photoacoustic imaging of MicroRNA in living mice","volume":"31","author":"Zhang","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.colsurfb.2025.115053_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.matdes.2020.108742","article-title":"Homotypic targeting and drug delivery in glioblastoma cells through cell membrane-coated boron nitride nanotubes","volume":"192","author":"De Pasquale","year":"2020","journal-title":"Mater. Des."},{"key":"10.1016\/j.colsurfb.2025.115053_bib51","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s11064-011-0701-1","article-title":"Drug resistance in glioblastoma: a mini review","volume":"37","author":"Haar","year":"2012","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.colsurfb.2025.115053_bib52","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10637-010-9569-1","article-title":"Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP","volume":"30","author":"de Vries","year":"2012","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.colsurfb.2025.115053_bib53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.canlet.2015.07.013","article-title":"Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells","volume":"367","author":"Munoz","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.colsurfb.2025.115053_bib54","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0093-7754(01)90210-6","article-title":"Oxygenation status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy","volume":"28","author":"VAUPEL","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib55","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/cells6040045","article-title":"The role of hypoxia in glioblastoma invasion","volume":"6","author":"Monteiro","year":"2017","journal-title":"Cells"},{"key":"10.1016\/j.colsurfb.2025.115053_bib56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0006-2952(99)00292-0","article-title":"Expression of hypoxia-inducible factor 1: mechanisms and consequences","volume":"59","author":"Semenza","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib57","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1111\/j.1742-4658.2007.06072.x","article-title":"Dual effect of echinomycin on hypoxia-inducible factor-1 activity under normoxic and hypoxic conditions","volume":"274","author":"Vlaminck","year":"2007","journal-title":"FEBS J."},{"key":"10.1016\/j.colsurfb.2025.115053_bib58","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.yexcr.2016.04.011","article-title":"Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment","volume":"343","author":"Tang","year":"2016","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.colsurfb.2025.115053_bib59","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/neuonc\/nos195","article-title":"Tumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1","volume":"14","author":"Chou","year":"2012","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib60","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO.2000.18.6.1254","article-title":"Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme","volume":"18","author":"Del Rowe","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib61","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1073\/pnas.91.6.2076","article-title":"Convection-enhanced delivery of macromolecules in the brain","volume":"91","author":"Bobo","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.colsurfb.2025.115053_bib62","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.3171\/2014.12.FOCUS14758","article-title":"Therapeutic strategies to improve drug delivery across the blood-brain barrier","volume":"38","author":"Azad","year":"2015","journal-title":"Neurosurg. Focus."},{"key":"10.1016\/j.colsurfb.2025.115053_bib63","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11060-024-04795-z","article-title":"Focused ultrasound-mediated enhancement of blood-brain barrier permeability for brain tumor treatment: a systematic review of clinical trials","volume":"170","author":"Zhu","year":"2024","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib64","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1148\/radiol.2202001804","article-title":"Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits","volume":"220","author":"Hynynen","year":"2001","journal-title":"Radiology"},{"key":"10.1016\/j.colsurfb.2025.115053_bib65","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1586\/14737140.6.11.1593","article-title":"Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates","volume":"6","author":"Simpson","year":"2006","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.colsurfb.2025.115053_bib66","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1046\/j.1471-4159.1998.70051781.x","article-title":"CNS drug design based on principles of blood-brain barrier transport","volume":"70","author":"Pardridge","year":"1998","journal-title":"J. Neurochem."},{"key":"10.1016\/j.colsurfb.2025.115053_bib67","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1210\/edrv-7-3-314","article-title":"Receptor-mediated peptide transport through the blood-brain barrier","volume":"7","author":"Pardridge","year":"1986","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.colsurfb.2025.115053_bib68","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jconrel.2007.11.001","article-title":"Brain targeting using novel lipid nanovectors","volume":"126","author":"B\u00e9duneau","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2025.115053_bib69","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.nurt.2009.01.018","article-title":"Nanotechnology for delivery of drugs to the brain for epilepsy","volume":"6","author":"Bennewitz","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.colsurfb.2025.115053_bib70","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4103\/2230-973X.147230","article-title":"Liposomal aloe vera trans-emulgel drug delivery of naproxen and nimesulide: a study","volume":"5","author":"Venkataharsha","year":"2015","journal-title":"Int. J. Pharm. Investig."},{"key":"10.1016\/j.colsurfb.2025.115053_bib71","doi-asserted-by":"crossref","DOI":"10.2174\/1385272820666161031161101","article-title":"Targeted delivery of lipid nanoparticles by means of surface chemical modification","volume":"21","author":"Gaspar","year":"2017","journal-title":"Curr. Org. Chem."},{"key":"10.1016\/j.colsurfb.2025.115053_bib72","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/17425247.2021.1902984","article-title":"Exploring the transformability of polymer-lipid hybrid nanoparticles and nanomaterial-biology interplay to facilitate tumor penetration, cellular uptake and intracellular targeting of anticancer drugs","volume":"18","author":"Amini","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.colsurfb.2025.115053_bib73","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.3390\/pharmaceutics15092233","article-title":"Recent advances in targeted drug delivery strategy for enhancing oncotherapy","volume":"15","author":"Li","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2025.115053_bib74","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12645-024-00275-1","article-title":"pH-sensitive polymeric micelles enhance the co-delivery of doxorubicin and docetaxel: an emerging modality for treating breast cancer","volume":"15","author":"Farhoudi","year":"2024","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib75","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.nano.2015.09.004","article-title":"Nanostructured lipid carriers: promising drug delivery systems for future clinics","volume":"12","author":"Beloqui","year":"2016","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.colsurfb.2025.115053_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.101022","article-title":"Ultrasound-enhanced precision tumor theranostics using cell membrane-coated and pH-responsive nanoclusters assembled from ultrasmall iron oxide nanoparticles","volume":"36","author":"Jia","year":"2021","journal-title":"Nano Today"},{"key":"10.1016\/j.colsurfb.2025.115053_bib77","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2025.115053_bib78","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1002\/jps.24002","article-title":"Solid lipid nanoparticles for potential doxorubicin delivery in glioblastoma treatment: preliminary in vitro studies","volume":"103","author":"Battaglia","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.colsurfb.2025.115053_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2021.111946","article-title":"Brain-targeted, drug-loaded solid lipid nanoparticles against glioblastoma cells in culture","volume":"206","author":"Ak","year":"2021","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.colsurfb.2025.115053_bib80","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1080\/01932691.2012.739535","article-title":"Caffeine encapsulated in small unilamellar liposomes: characerization and in vitro release profile","volume":"34","author":"Chorilli","year":"2013","journal-title":"J. Dispers. Sci. Technol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib81","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2017.08.033","article-title":"Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases","volume":"264","author":"Tapeinos","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2025.115053_bib82","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2217\/nnm-2017-0230","article-title":"Nanoparticle\/siRNA-based therapy strategies in glioma: which nanoparticles, which siRNAs?","volume":"13","author":"Aigner","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.colsurfb.2025.115053_bib83","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.18632\/oncotarget.2267","article-title":"Multifunctional targeting daunorubicin plus quinacrine liposomes, modified by wheat germ agglutinin and tamoxifen, for treating brain glioma and glioma stem cells","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.colsurfb.2025.115053_bib84","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/neuonc\/nos305","article-title":"Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts","volume":"15","author":"Chen","year":"2013","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib85","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2012.02.009","article-title":"Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose","volume":"81","author":"Niu","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2025.115053_bib86","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.colsurfb.2008.11.033","article-title":"Modulation of the physicochemical state of interior agents to prepare controlled release liposomes","volume":"69","author":"Wang","year":"2009","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.colsurfb.2025.115053_bib87","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.cclet.2021.01.014","article-title":"Nanomaterials toward the treatment of Alzheimer\u2019s disease: recent advances and future trends","volume":"32","author":"Zeng","year":"2021","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.colsurfb.2025.115053_bib88","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.cclet.2021.01.001","article-title":"STING-activating drug delivery systems: design strategies and biomedical applications","volume":"32","author":"Li","year":"2021","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.colsurfb.2025.115053_bib89","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3390\/molecules27041372","article-title":"A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.colsurfb.2025.115053_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115355","article-title":"Zn phthalocyanines loaded into liposomes: characterization and enhanced performance of photodynamic activity on glioblastoma cells","volume":"28","author":"Miretti","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.colsurfb.2025.115053_bib91","first-page":"399","article-title":"A review of properties, delivery systems and analytical methods for the characterization of monomeric glycoprotein transferrin","volume":"51","author":"Fernandes","year":"2021","journal-title":"Crit. Rev. Anal. Chem."},{"key":"10.1016\/j.colsurfb.2025.115053_bib92","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-024-01574-1","article-title":"Lipid-based nanosystems: the next generation of cancer immune therapy","volume":"17","author":"Cheng","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910382","article-title":"Enhanced photodynamic therapy efficacy through solid lipid nanoparticle of Purpurin-18-N-Propylimide methyl ester for cancer treatment","volume":"25","author":"Yeo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.colsurfb.2025.115053_bib94","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.3390\/app9224961","article-title":"Quantification of Trans-Resveratrol-Loaded solid lipid nanoparticles by a validated Reverse-Phase HPLC photodiode array","volume":"9","author":"Rigon","year":"2019","journal-title":"Appl. Sci."},{"key":"10.1016\/j.colsurfb.2025.115053_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11020065","article-title":"Methotrexate-Loaded solid lipid nanoparticles: protein functionalization to improve brain biodistribution","volume":"11","author":"Muntoni","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2025.115053_bib96","doi-asserted-by":"crossref","first-page":"26777","DOI":"10.1039\/D0RA03491F","article-title":"A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems","volume":"10","author":"Duan","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.colsurfb.2025.115053_bib97","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejpb.2018.11.017","article-title":"Solid lipid nanoparticles for the delivery of anti-microbial oligonucleotides","volume":"134","author":"Gonz\u00e1lez-Paredes","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2025.115053_bib98","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijpharm.2013.08.070","article-title":"A novel approach to oral iron delivery using ferrous sulphate loaded solid lipid nanoparticles","volume":"456","author":"Zariwala","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2025.115053_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.111305","article-title":"Solid lipid nanoparticles for enhanced oral absorption: a review","volume":"196","author":"Salah","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.colsurfb.2025.115053_bib100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1208\/s12249-021-02186-5","article-title":"Transdermal delivery of Curcumin-Loaded solid lipid nanoparticles as microneedle patch: an in vitro and in vivo study","volume":"23","author":"Prabhu","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.colsurfb.2025.115053_bib101","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/gels8010058","article-title":"Self-Gelling solid lipid nanoparticle hydrogel containing simvastatin as suitable wound dressing: an investigative study","volume":"8","author":"Gupta","year":"2022","journal-title":"Gels"},{"key":"10.1016\/j.colsurfb.2025.115053_bib102","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/03639045.2017.1391835","article-title":"Development and characterization of cationic solid lipid nanoparticles for co-delivery of pemetrexed and miR-21 antisense oligonucleotide to glioblastoma cells","volume":"44","author":"K\u00fc\u00e7\u00fckt\u00fcrkmen","year":"2018","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.colsurfb.2025.115053_bib103","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2217\/nnm-2018-0436","article-title":"Nutlin-loaded magnetic solid lipid nanoparticles for targeted glioblastoma treatment","volume":"14","author":"Grillone","year":"2019","journal-title":"Nanomed. (Lond. )"},{"key":"10.1016\/j.colsurfb.2025.115053_bib104","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/17425247.2020.1727883","article-title":"SLN and NLC for topical, dermal, and transdermal drug delivery","volume":"17","author":"Souto","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.colsurfb.2025.115053_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12020126","article-title":"Improving the oral bioavailability of an Anti-Glioma prodrug CAT3 using novel solid lipid nanoparticles containing oleic Acid-CAT3 conjugates","volume":"12","author":"Wang","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2025.115053_bib106","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejpb.2016.10.015","article-title":"Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues","volume":"109","author":"Balguri","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2025.115053_bib107","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3109\/1061186X.2012.716845","article-title":"Nanostructured lipid carriers system: recent advances in drug delivery","volume":"20","author":"Iqbal","year":"2012","journal-title":"J. Drug Target."},{"key":"10.1016\/j.colsurfb.2025.115053_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119705","article-title":"Topical nanostructured lipid carrier gel of quercetin and resveratrol: formulation, optimization, in vitro and ex vivo study for the treatment of skin cancer","volume":"587","author":"Imran","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2025.115053_bib109","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00210-024-03408-w","article-title":"Leveraging nanostructured lipid carriers to enhance targeted delivery and efficacy in breast cancer therapy: a comprehensive review","volume":"398","author":"Naseem","year":"2025","journal-title":"Naunyn. Schmiede Arch. Pharmacol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib110","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/10837450.2016.1189933","article-title":"Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using Box-Behnken design","volume":"22","author":"Emami","year":"2017","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib111","first-page":"3","article-title":"Targeting cancer using cholesterol conjugates","volume":"22","author":"Radwan","year":"2014","journal-title":"Saudi Pharm. J. SPJ Off. Publ. Saudi Pharm. Soc."},{"key":"10.1016\/j.colsurfb.2025.115053_bib112","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.2147\/IJN.S161163","article-title":"Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy","volume":"13","author":"Zhang","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2025.115053_bib113","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S0928-0987(00)00161-5","article-title":"Rationale and applications of lipids as prodrug carriers","volume":"11","author":"Lambert","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.colsurfb.2025.115053_bib114","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40199-018-0209-1","article-title":"Lipid-drug conjugates: a potential nanocarrier system for oral drug delivery applications","volume":"26","author":"Banerjee","year":"2018","journal-title":"DARU J. Pharm. Sci."},{"key":"10.1016\/j.colsurfb.2025.115053_bib115","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1080\/10611860701499946","article-title":"Antitumor activity of new liposomal prodrug of mitomycin c in multidrug resistant solid tumor: insights of the mechanism of action","volume":"15","author":"Zalipsky","year":"2007","journal-title":"J. Drug Target."},{"key":"10.1016\/j.colsurfb.2025.115053_bib116","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1021\/jm201653u","article-title":"Synthesis, anticancer activities, and cellular uptake studies of lipophilic derivatives of doxorubicin succinate","volume":"55","author":"Chhikara","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.colsurfb.2025.115053_bib117","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jconrel.2007.09.007","article-title":"Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme","volume":"124","author":"Nikanjam","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2025.115053_bib118","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/acs.molpharmaceut.6b01027","article-title":"Lipid\u2013Drug conjugate for enhancing drug delivery","volume":"14","author":"Irby","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.colsurfb.2025.115053_bib119","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1556-276X-8-102","article-title":"Liposome: classification, preparation, and applications","volume":"8","author":"Akbarzadeh","year":"2013","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.colsurfb.2025.115053_bib120","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib121","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1039\/C9TB02470K","article-title":"Development of functional liposomes by modification of stimuli-responsive materials and their biomedical applications","volume":"8","author":"Yuba","year":"2020","journal-title":"J. Mater. Chem. B."},{"key":"10.1016\/j.colsurfb.2025.115053_bib122","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1615\/CritRevBiomedEng.2017021249","article-title":"Thermal therapy approaches for treatment of brain tumors in animals and humans","volume":"44","author":"Bredlau","year":"2016","journal-title":"Crit. Rev. Biomed. Eng."},{"key":"10.1016\/j.colsurfb.2025.115053_bib123","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1450","article-title":"Stimuli-responsive liposomes for drug delivery","volume":"9","author":"Lee","year":"2017","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib124","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jconrel.2017.01.025","article-title":"To heat or not to heat: challenges with clinical translation of thermosensitive liposomes","volume":"249","author":"Dou","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2025.115053_bib125","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/02656730410001703186","article-title":"Therapeutic efficacy of targeting chemotherapy using local hyperthermia and thermosensitive liposome: evaluation of drug distribution in a rat glioma model","volume":"20","author":"Aoki","year":"2004","journal-title":"Int. J. Hyperth."},{"key":"10.1016\/j.colsurfb.2025.115053_bib126","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.nano.2015.03.014","article-title":"Image guided drug release from pH-sensitive ion channel-functionalized stealth liposomes into an in vivo glioblastoma model","volume":"11","author":"Pacheco-Torres","year":"2015","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.colsurfb.2025.115053_bib127","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/1061186X.2017.1419361","article-title":"Current update of a thermosensitive liposomes composed of DPPC and Brij78","volume":"26","author":"Ho","year":"2018","journal-title":"J. Drug Target."},{"key":"10.1016\/j.colsurfb.2025.115053_bib128","doi-asserted-by":"crossref","first-page":"15057","DOI":"10.1039\/C9NR03931G","article-title":"Glioma-targeted dual functionalized thermosensitive Ferri-liposomes for drug delivery through an in vitro blood-brain barrier","volume":"11","author":"Shi","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.colsurfb.2025.115053_bib129","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2020.00205","article-title":"Magnetic Temperature-Sensitive Solid-Lipid particles for targeting and killing tumor cells","volume":"8","author":"\u015awi\u0119tek","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.colsurfb.2025.115053_bib130","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1211\/jpp.59.4.0001","article-title":"pH-sensitive liposomes--principle and application in cancer therapy","volume":"59","author":"Karanth","year":"2007","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib131","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.nano.2015.03.014","article-title":"Image guided drug release from pH-sensitive ion channel-functionalized stealth liposomes into an in vivo glioblastoma model","volume":"11","author":"Pacheco-Torres","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.colsurfb.2025.115053_bib132","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1296091","article-title":"Lipid-based nanoparticles as drug delivery carriers for cancer therapy","volume":"14","author":"Waheed","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib133","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.7150\/thno.38069","article-title":"Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics","volume":"10","author":"Mi","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.colsurfb.2025.115053_bib134","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201606628","article-title":"Rational design of cancer nanomedicine: nanoproperty integration and synchronization","volume":"29","author":"Sun","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.colsurfb.2025.115053_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2022.112999","article-title":"Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): a current overview of active targeting in brain diseases","volume":"221","author":"Teixeira","year":"2023","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.colsurfb.2025.115053_bib136","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1002\/adma.201205292","article-title":"In vivo Bio-Safety evaluations and Diagnostic\/Therapeutic applications of chemically designed mesoporous silica nanoparticles","volume":"25","author":"Chen","year":"2013","journal-title":"Adv. Mater."},{"key":"10.1016\/j.colsurfb.2025.115053_bib137","first-page":"445","article-title":"A critical review of biological properties, delivery systems and Analytical\/Bioanalytical methods for determination of bevacizumab","volume":"51","author":"Filippo","year":"2021","journal-title":"Crit. Rev. Anal. Chem."},{"key":"10.1016\/j.colsurfb.2025.115053_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116113","article-title":"Lipid-based nanoparticles to address the limitations of GBM therapy by overcoming the blood-brain barrier, targeting glioblastoma stem cells, and counteracting the immunosuppressive tumor microenvironment","volume":"171","author":"Zhao","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.colsurfb.2025.115053_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.onano.2023.100128","article-title":"Nanoparticle-based drug delivery across the blood-brain barrier for treating malignant brain glioma","volume":"10","author":"Kurawattimath","year":"2023","journal-title":"OpenNano"},{"key":"10.1016\/j.colsurfb.2025.115053_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2023.102871","article-title":"Lipid-core nanoparticles: classification, preparation methods, routes of administration and recent advances in cancer treatment","volume":"314","author":"Grav\u00e1n","year":"2023","journal-title":"Adv. Colloid Interface Sci."},{"key":"10.1016\/j.colsurfb.2025.115053_bib141","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2174\/1871527315666160915120758","article-title":"Merging transport data for choroid plexus with Blood-Brain barrier to model CNS homeostasis and disease more effectively","volume":"15","author":"Johanson","year":"2016","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.colsurfb.2025.115053_bib142","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/pharmaceutics11030113","article-title":"Strategies to enhance drug absorption via nasal and pulmonary routes","volume":"11","author":"Ghadiri","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2025.115053_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09517","article-title":"Intranasal delivery in glioblastoma treatment: prospective molecular treatment modalities","volume":"8","author":"Morales","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.colsurfb.2025.115053_bib144","doi-asserted-by":"crossref","first-page":"12343","DOI":"10.2147\/IJN.S497480","article-title":"Nose to brain: exploring the progress of intranasal delivery of solid lipid nanoparticles and nanostructured lipid carriers","volume":"Volume 19","author":"Zheng","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2025.115053_bib145","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3109\/10717544.2014.975382","article-title":"Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study","volume":"23","author":"Madane","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.colsurfb.2025.115053_bib146","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1021\/acs.molpharmaceut.6b00586","article-title":"Brain targeting of temozolomide via the intranasal route using Lipid-Based nanoparticles: brain pharmacokinetic and scintigraphic analyses","volume":"13","author":"Khan","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.colsurfb.2025.115053_bib147","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.drudis.2019.10.005","article-title":"Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook","volume":"25","author":"Sabir","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.colsurfb.2025.115053_bib148","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1002\/ijc.30398","article-title":"Curcumin changes the polarity of tumor-associated microglia and eliminates glioblastoma","volume":"139","author":"Mukherjee","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.colsurfb.2025.115053_bib149","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/ijc.29095","article-title":"Inhibition of glioma progression by a newly discovered CD38 inhibitor","volume":"136","author":"Blacher","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.colsurfb.2025.115053_bib150","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jconrel.2017.06.032","article-title":"A potential non-invasive glioblastoma treatment: Nose-to-brain delivery of farnesylthiosalicylic acid incorporated hybrid nanoparticles","volume":"261","author":"Sekerdag","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2025.115053_bib151","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.gene.2013.11.077","article-title":"Analysis of DNA repair gene polymorphisms in glioblastoma","volume":"536","author":"Rodriguez-Hernandez","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.colsurfb.2025.115053_bib152","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.canlet.2012.05.033","article-title":"Glioblastoma cancer stem cells \u2013 from concept to clinical application","volume":"338","author":"Stopschinski","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.colsurfb.2025.115053_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188616","article-title":"Elucidating the mechanisms of temozolomide resistance in gliomas and the strategies to overcome the resistance","volume":"1876","author":"Tomar","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.colsurfb.2025.115053_bib154","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejpb.2021.08.011","article-title":"Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers","volume":"168","author":"Delello Di Filippo","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2025.115053_bib155","article-title":"Overcoming biological barriers BBB\/BBTB by designing PUFA functionalised lipid-based nanocarriers for glioblastoma targeted therapy","volume":"155","author":"Zwain","year":"2023","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.colsurfb.2025.115053_bib156","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/pharmaceutics15020687","article-title":"Glioblastoma multiforme: probing solutions to systemic toxicity towards High-Dose chemotherapy and inflammatory influence in resistance against temozolomide","volume":"15","author":"Nasir","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2025.115053_bib157","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.3109\/10717544.2015.1058434","article-title":"Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery","volume":"23","author":"Wu","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.colsurfb.2025.115053_bib158","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/ijms21010273","article-title":"Delivery of Nanoparticle-Based radiosensitizers for radiotherapy applications","volume":"21","author":"Boateng","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.colsurfb.2025.115053_bib159","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.biomaterials.2017.01.001","article-title":"Development of a hypoxia-triggered and hypoxic radiosensitized liposome as a doxorubicin carrier to promote synergetic chemo-\/radio-therapy for glioma","volume":"121","author":"Liu","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.colsurfb.2025.115053_bib160","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.2174\/1568026620666200826122402","article-title":"Cellular and molecular targeted drug delivery in central nervous system cancers: advances in targeting strategies","volume":"20","author":"Zhao","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.colsurfb.2025.115053_bib161","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.7150\/thno.26225","article-title":"Hypoxia-responsive lipid-poly-(hypoxic radiosensitized polyprodrug) nanoparticles for glioma chemo- and radiotherapy","volume":"8","author":"Hua","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.colsurfb.2025.115053_bib162","doi-asserted-by":"crossref","first-page":"23714","DOI":"10.1073\/pnas.1906346116","article-title":"Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma","volume":"116","author":"Zhang","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.colsurfb.2025.115053_bib163","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s11095-021-03122-9","article-title":"Optimizing the design of Blood\u2013Brain Barrier-Penetrating Polymer-Lipid-Hybrid nanoparticles for delivering anticancer drugs to glioblastoma","volume":"38","author":"Ahmed","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.colsurfb.2025.115053_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114035","article-title":"Smart biomaterials to enhance the efficiency of immunotherapy in glioblastoma: state of the art and future perspectives","volume":"179","author":"Abadi","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2025.115053_bib165","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s11060-017-2413-0","article-title":"Immunotherapy and radiation in glioblastoma","volume":"134","author":"Sahebjam","year":"2017","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib166","article-title":"Advancing cancer immunotherapies with nanotechnology","volume":"2","author":"Lou","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.colsurfb.2025.115053_bib167","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41401-020-0429-z","article-title":"Nanomedicine-based immunotherapy for central nervous system disorders","volume":"41","author":"Hanif","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.colsurfb.2025.115053_bib168","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1158\/0008-5472.CAN-18-0306","article-title":"Nanoparticles that reshape the tumor milieu create a therapeutic window for effective T-cell therapy in solid malignancies","volume":"78","author":"Zhang","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.colsurfb.2025.115053_bib169","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40005-021-00548-6","article-title":"Multifunctional lipidic nanocarriers for effective therapy of glioblastoma: recent advances in stimuli-responsive, receptor and subcellular targeted approaches","volume":"52","author":"Hegde","year":"2022","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.colsurfb.2025.115053_bib170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12951-020-00589-3","article-title":"Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules","volume":"18","author":"Pinton","year":"2020","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106999","article-title":"Novel thermosensitive small multilamellar lipid nanoparticles with promising release characteristics made by dual centrifugation","volume":"206","author":"Koehler","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.colsurfb.2025.115053_bib172","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijpharm.2016.03.005","article-title":"Magnetic solid lipid nanoparticles in hyperthermia against colon cancer","volume":"504","author":"Mu\u00f1oz de Escalona","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2025.115053_bib173","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/antiox11040625","article-title":"Hyperthermia treatment as a promising Anti-Cancer strategy: therapeutic targets, perspective mechanisms and synergistic combinations in experimental approaches","volume":"11","author":"Yi","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.colsurfb.2025.115053_bib174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02656730118511","article-title":"Hyperthermia in oncology","volume":"17","author":"Issels","year":"2001","journal-title":"Int. J. Hyperth."},{"key":"10.1016\/j.colsurfb.2025.115053_bib175","doi-asserted-by":"crossref","first-page":"550","DOI":"10.15252\/emmm.201505890","article-title":"<scp>MET<\/scp> inhibition overcomes radiation resistance of glioblastoma stem-like cells","volume":"8","author":"De Bacco","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.colsurfb.2025.115053_bib176","first-page":"271","article-title":"Cancer stem cells and chemoresistance in glioblastoma multiform: a review article","volume":"10","author":"Safari","year":"2015","journal-title":"J. Stem Cells"},{"key":"10.1016\/j.colsurfb.2025.115053_bib177","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib178","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/pharmaceutics13081183","article-title":"Solid lipid nanoparticles (SLNs): an advanced drug delivery system targeting brain through BBB","volume":"13","author":"Satapathy","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2025.115053_bib179","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ejpb.2014.05.004","article-title":"Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art","volume":"87","author":"Gastaldi","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2025.115053_bib180","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1126\/science.1553558","article-title":"Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system","volume":"255","author":"Reynolds","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.colsurfb.2025.115053_bib181","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.2147\/OTT.S160685","article-title":"Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis","volume":"Volume 11","author":"Song","year":"2018","journal-title":"Onco. Targets"},{"key":"10.1016\/j.colsurfb.2025.115053_bib182","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.msec.2018.07.011","article-title":"Triggered release of paclitaxel from magnetic solid lipid nanoparticles by magnetic hyperthermia","volume":"92","author":"Oliveira","year":"2018","journal-title":"Mater. Sci. Eng. C."},{"key":"10.1016\/j.colsurfb.2025.115053_bib183","doi-asserted-by":"crossref","first-page":"18441","DOI":"10.1021\/acsnano.3c06085","article-title":"Drug-Loaded lipid magnetic nanoparticles for combined local hyperthermia and chemotherapy against glioblastoma multiforme","volume":"17","author":"Beola","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.colsurfb.2025.115053_bib184","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3390\/pharmaceutics15030818","article-title":"Paclitaxel-Loaded Lipid-Coated magnetic nanoparticles for dual Chemo-Magnetic hyperthermia therapy of melanoma","volume":"15","author":"Oliveira","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2025.115053_bib185","doi-asserted-by":"crossref","first-page":"8325","DOI":"10.2147\/IJN.S147506","article-title":"Solid lipid nanoparticles for thermoresponsive targeting: evidence from spectrophotometry, electrochemical, and cytotoxicity studies","volume":"Volume 12","author":"Rehman","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2025.115053_bib186","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1021\/acsabm.3c00695","article-title":"Modern photodynamic glioblastoma therapy using Curcumin- or Parietin-Loaded lipid nanoparticles in a CAM model study","volume":"6","author":"Schulze","year":"2023","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.colsurfb.2025.115053_bib187","doi-asserted-by":"crossref","first-page":"33366","DOI":"10.1021\/acsnano.4c08448","article-title":"Anti-PD-L1 antibody fragment linked to Tumor-Targeting lipid nanoparticle can eliminate cancer and its metastasis via photoimmunotherapy","volume":"18","author":"Park","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.colsurfb.2025.115053_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2024.167641","article-title":"Bilirubin nanoparticles modulate Treg\/Th17 cells and functional metabolism of gut microbiota to inhibit lung adenocarcinoma","volume":"1871","author":"Zhu","year":"2025","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.colsurfb.2025.115053_bib189","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.3390\/ijms19123905","article-title":"Intranasal perillyl alcohol for glioma therapy: molecular mechanisms and clinical development","volume":"19","author":"Chen","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.colsurfb.2025.115053_bib190","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00432-010-0873-0","article-title":"Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma","volume":"137","author":"da Fonseca","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib191","first-page":"5625","article-title":"Long-term outcome in patients with recurrent malignant glioma treated with perillyl alcohol inhalation","volume":"33","author":"Fonseca","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.colsurfb.2025.115053_bib192","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.surneu.2007.07.040","article-title":"Preliminary results from a phase I\/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas","volume":"70","author":"da Fonseca","year":"2008","journal-title":"Surg. Neurol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib193","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119283","article-title":"Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: nanomedicine approaches to improve their efficacy","volume":"581","author":"Aparicio-Blanco","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2025.115053_bib194","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.nec.2020.12.002","article-title":"Molecularly targeted clinical trials","volume":"32","author":"Smith-Cohn","year":"2021","journal-title":"Neurosurg. Clin. N. Am."},{"key":"10.1016\/j.colsurfb.2025.115053_bib195","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.3390\/cancers15072116","article-title":"Mechanisms of resistance and current treatment options for glioblastoma multiforme (GBM)","volume":"15","author":"Yalamarty","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.colsurfb.2025.115053_bib196","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1168454","article-title":"Insight into lipid-based nanoplatform-mediated drug and gene delivery in neuro-oncology and their clinical prospects","volume":"13","author":"Hegde","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib197","article-title":"Lipid nanoparticles for the treatment of glioblastoma multiforme: current status of research and clinical translation","volume":"108","author":"Kulkarni","year":"2025","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib198","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00280-017-3247-3","article-title":"A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma","volume":"79","author":"Clarke","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib199","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/1471-2407-9-308","article-title":"RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study","volume":"9","author":"Beier","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.colsurfb.2025.115053_bib200","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1049\/nbt2.12111","article-title":"The comparison of biodistribution of glutathione PEGylated nanoliposomal doxorubicin formulations prepared by pre-insertion and post-insertion methods for brain delivery in normal mice","volume":"17","author":"Mehrabian","year":"2023","journal-title":"IET Nanobiotechnol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100365","article-title":"Targeting immunoliposomes to EGFR-positive glioblastoma","volume":"7","author":"Kasenda","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.colsurfb.2025.115053_bib202","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3390\/jpm13091328","article-title":"Nanoparticle-Based treatment in glioblastoma","volume":"13","author":"Roque","year":"2023","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.colsurfb.2025.115053_bib203","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/scientificamerican0794-58","article-title":"Barriers to drug delivery in solid tumors","volume":"271","author":"Jain","year":"1994","journal-title":"Sci. Am."},{"key":"10.1016\/j.colsurfb.2025.115053_bib204","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood\u2013brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.colsurfb.2025.115053_bib205","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: overcoming blood\u2013brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2025.115053_bib206","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.colsurfb.2025.115053_bib207","doi-asserted-by":"crossref","DOI":"10.3390\/nano9040638","article-title":"Lipid-Based nanoparticles: application and recent advances in cancer treatment","volume":"9","author":"Garc\u00eda-Pinel","year":"2019","journal-title":"Nanomater"},{"key":"10.1016\/j.colsurfb.2025.115053_bib208","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","article-title":"K. M\u00e4der, Solid lipid nanoparticles: production, characterization and applications","volume":"47","author":"Mehnert","year":"2001","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Colloids and Surfaces B: Biointerfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776525005600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776525005600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T03:04:13Z","timestamp":1757300653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0927776525005600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":208,"alternative-id":["S0927776525005600"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfb.2025.115053","relation":{},"ISSN":["0927-7765"],"issn-type":[{"value":"0927-7765","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unlocking the potential of lipid nanoparticles for enhanced glioma therapy: Recent advancements and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Colloids and Surfaces B: Biointerfaces","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.colsurfb.2025.115053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115053"}}